“以前用药一针3800元，现在进了医保自付只要七八百元。”一位银屑病患者向《证券日报》记者算的这笔账，折射出国产创新药正加速从“做出来”迈向“用得上”。 近年来，国家医疗保障局（以下简称“国家医保局”）依托医保药品目录动态调整、创新药谈判规则优化，在药企、患者与产业发展之间搭起桥梁。 近日，《证券日报》记者跟随国家医保局组织的媒体调研团，走进广东东阳光药业股份有限公司（以下简称“东阳光药”）、...
Source Link“以前用药一针3800元，现在进了医保自付只要七八百元。”一位银屑病患者向《证券日报》记者算的这笔账，折射出国产创新药正加速从“做出来”迈向“用得上”。 近年来，国家医疗保障局（以下简称“国家医保局”）依托医保药品目录动态调整、创新药谈判规则优化，在药企、患者与产业发展之间搭起桥梁。 近日，《证券日报》记者跟随国家医保局组织的媒体调研团，走进广东东阳光药业股份有限公司（以下简称“东阳光药”）、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.